What do systematic reviews say?

Fondaparinux vs heparin

Fondaparinux showed no clear difference in major bleeding compared with heparin (low certainty).

• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
  RR 0.82 [0.4, 1.66]
  1 study · 477 participants
  Low

Fondaparinux vs placebo

Fondaparinux showed no clear difference in major bleeding compared with placebo (moderate certainty).

• Treatment for superficial thrombophlebitis of the leg 2018 · Cochrane Headline outcomes only
  RR 0.99 [0.06, 15.86]
  1 study · 2987 participants
  Moderate

Fondaparinux vs low molecular weight heparin

Fondaparinux leads to higher major bleeding compared with LMWH (high certainty).

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  RR 1.38 [1.09, 1.75]
  11 studies · 12501 participants
  High

Fondaparinux vs variable dose warfarin

It is very uncertain whether fondaparinux changes major bleeding compared with variable dose warfarin (very low certainty).

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  RR 7 [0.37, 134.05]
  1 study · 236 participants
  Very low

Fondaparinux vs 1 mg warfarin

It is very uncertain whether fondaparinux changes major bleeding compared with 1 mg warfarin (very low certainty).

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  RR 3 [0.32, 28.43]
  1 study · 236 participants
  Very low

Fondaparinux vs edoxaban

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 38 participants
  Very low

Fondaparinux vs mechanical thromboprophylaxis

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 120 participants
  Low

Fondaparinux vs placebo

Fondaparinux probably leads to higher major bleeding compared with placebo (moderate certainty).

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  RR 2.56 [1.48, 4.44]
  8 studies · 6659 participants
  Moderate

Fondaparinux plus vitamin K antagonist vs usual care

Fondaparinux plus vitamin K antagonist showed no clear difference in major bleeding during the initial treatment compared with standard therapy (moderate certainty).

• Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
  RR 1.15 [0.39, 3.44]
  2 studies · 2645 participants
  Moderate
• Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
  RR 1.05 [0.64, 1.71]
  2 studies · 2645 participants
  Moderate